Oppenheimer raised the firm’s price target on Sagimet Biosciences (SGMT) to $33 from $28 and keeps an Outperform rating on the shares. The firm notes the company hosted Dr. Julie Harper to unpack deni’s potential in acne, following management’s strategic pivot to derm. Oppenheimer is incrementally optimistic about deni’s disruptive potential in acne.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGMT: